Effectiveness of the Treatment with Botulinum Toxin Type A (BTX-A) in the Management of the Spasticity in Patients with Amyotrophic Lateral Sclerosis (ALS)

Publisher： Bentham Science Publishers

ISSN： 2212-7070

Source： Clinical Immunology, Endocrine & Metabolic Drugs, Vol.3, Iss.1, 2016-06, pp. : 73-77

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease

By  

Current Pharmaceutical Design, Vol. 22, Iss. 6, 2016-02 ,pp. : 758-763

Bentham Science Publishers

Access to resources Recommend Favorite

Botulinum toxin in the management of spasticity in adults

By Turner-Stokes Lynne   Ward Anthony  

Clinical Medicine, Vol. 2, Iss. 2, 2002-03 ,pp. : 128-130

Royal College Of Physicians

Access to resources Recommend Favorite

The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis

By Bensimon Gilbert   Doble Adam  

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 525-534

Informa Healthcare

Access to resources Recommend Favorite

Management of Amyotrophic Lateral Sclerosis

By Corcia Philippe   Meininger Vincent  

Drugs, Vol. 68, Iss. 8, 2008-01 ,pp. : 1037-1048

Adis International

Access to resources Recommend Favorite

Clinical investigation of medicinal products for treatment of amyotrophic lateral sclerosis (ALS)

By  

European Neuropsychopharmacology, Vol. 11, Iss. 2, 2001-04 ,pp. : 187-189

Elsevier

Access to resources Recommend Favorite